Key Insights

Highlights

Treatment Research

5 treatments under study, led by Normal Saline

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Early Phase 1 (1)
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Unknown3

Clinical Trials (3)

Showing 3 of 3 trials
NCT05872659Early Phase 1Unknown

Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection

NCT02648516Phase 1/2Unknown

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients

NCT01213186Phase 2Unknown

Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients

Showing all 3 trials

Research Network

Common Treatments

  • Normal Saline1
  • Conventional Plus Aait1
  • Mesenchymal Stem Cells1
  • High Dose Of Msc1
  • Low Dose Of Msc Treatment1

Active Sponsors

  • Fu-Sheng Wang1
  • Beijing 302 Hospital1
  • Shandong Public Health Clinical Center1
  • Shandong Qilu Cell Therapy Engineering Technology Co., Ltd1

Top Investigators

Related Conditions

  • Human Immunodeficiency Virus2
  • Aids Virus1

Activity Timeline